VERICI DX PLC

Management Reports • Mar 2, 2021

National Storage Mechanism | Additional information

RNS Number : 7717Q

Verici Dx PLC

02 March 2021

Verici Dx plc

("Verici Dx" or the "Company") 

First clinical trial sites initiated in US

Three leading US centres first to collaborate with Verici in clinical validation trial for lead products

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has partnered with Lorenzo Gallon, MD, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, MD, at Henry Ford Health System and Daniel G. Maluf, MD, at the University of Maryland, Baltimore to collaborate on Verici Dx's clinical trial surrounding its two lead products, ClaravaTM and TutevaTM, and longer term, the validation of the fibrosis test.

The study uses next generation sequencing in the Verici Dx laboratory to create transcriptomic profiles to validate performance characteristics of the lead Verici Dx immune-phenotype signature tests.

Professor of Medicine (Nephrology and Hypertension) and Surgery (Organ Transplantation), Dr. Gallon is an alumnus of the University of Padua Medical School, Italy and is the Medical Director of the Translational Medicine Programme, the Director of International Relations and the Director of the Renal Transplant Fellowship at Northwestern University.

Dr. Samaniego is the Medical Director of Kidney and Kidney Pancreas Transplantation and Director of Research and Outreach Kidney Transplant Program the Henry Ford Transplant Institute with over 21 years of experience. She completed her residency at Baylor College of Medicine and her fellowship at Johns Hopkins Hospital. She is an American Society of Nephrology and American College of Physicians fellow, and her research has been focused on antibody-mediated rejection and studying new immunosuppression approaches to optimize the success of kidney transplants.

Dr. Maluf, Director of the Program in Transplantation at the University of Maryland School of Medicine, performs renal transplantation at the University of Maryland Medical Centre. He has clinical and scientific expertise in kidney and liver transplantation, including living donor liver transplantation. Dr. Maluf is nationally and internationally recognized for his work with the American Transplant Society and the International Liver Transplant Society.

Sara Barrington, CEO of Verici Dx, said:

"We are delighted at the level of global interest in our validation trial and highly appreciative that these centres were able to lead our first clinical trials in the United States. Lorenzo, Milagros and Daniel have excellent, demonstrable track records in the medical industry, and have collectively helped pioneer organ transplant research in the modern era. We are excited to be onboarding more US sites shortly and are currently progressing with a number of EU sites to ensure that the two leading products are fully tested for validation by the end of the year."

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
N+1 Singer (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell / Justin McKeegan / Tom Salvesen
Walbrook PR Limited	Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen	Mob: 07980 541 893 / 07748 651 727

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RESDFLFBFXLZBBV